Executive hiring in U.S. pharma is taking longer, shortlists are thinner, finalists hesitate and boards second-guess. It is easy to blame “talent shortages” but what’s actually happening is more specific. The job has changed faster than the candidate pool has evolved. Boards now expect one executive to carry scientific credibility, financial discipline, and regulatory judgment...
It’s time to get your regulatory systems in check in 2026. With the regulatory changes going into effect this year, it’s becoming easier for regulators to see inconsistencies in your data and easier for inspectors to test whether your quality system actually works. Two developments drive this shift: In the European Union, EUDAMED becomes mandatory under the Medical Device Regulation In the United States, the...
Executive Summary Life sciences deal activity entering Q2 2026 is being driven by a narrower, more disciplined logic than the market saw in earlier biotech cycles. Strategic buyers are concentrating on assets that are close enough to approval, launch, or scaled clinical adoption that revenue visibility is real. This logic is...
Hiring leaders across U.S. R&D teams are running into a familiar problem. The candidate pipeline looks strong. Technical assessments check out. Interviews go well. Then, late in the process, momentum breaks. Offers stall. Candidates hesitate. Some walk away entirely. This pattern is not driven by compensation alone or by skill mismatches. Recent placements across research,...
The pharmaceutical industry is on the cusp of a massive investment wave in 2026 and it’s not just incremental growth. We’re talking multi-billion-dollar plant builds, blockbuster mergers and acquisitions (M&A), skyrocketing venture capital inflows, and strategic bets on frontier technologies like AI drug discovery. Whether you’re an investor, industry professional, or healthcare enthusiast, understanding these moves will...
